1[1]Stephens RJ, Fairlamb N, Gower N, et al. The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting. Proc Am Soc Clin Oncol,2002,21:291a.
2[2]Effects of vinorelbine on quality of life and survival in elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group. J Natl Cancer Inst,1999,91(1):66-72.
3[3]Lilenbaum RC, Herndon JE, List M, et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: a CALGB randomized trial of efficacy, quality of life and cost-effectiveness. Proc Am Soc Clin Oncol,2002,21:1a.
4[4]Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase Ⅲ randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol,2002,20(21):4285-4291.
5[5]Fossella FV, DeVore R, Kerr RN, et al. Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol,2000,18(12):2354-2362.
6[6]America Society of Clinical Oncology: Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol,1997,15(8):2996-3018.
7[7]Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol,2001,19(5):1336-1343.
8[8]Socinski MA, Schell MJ, Peterman A, et al. Phase Ⅲ trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage ⅢB/Ⅳ non-small-cell lung cancer. J Clin Oncol,2002,20(5):1335-1343.
9[9]Socinski MA, Baggstrom MQ, Hensing TA. Duration of therapy in advanced, metastatic non-small-cell lung cancer. Clin Adv Hemato Oncol,2003,1(1):33-38.
10[10]DePierre A, Quoix E, Mercier M, et al. Maintenance chemotherapy in advanced non-small-cell lung cancer: a randomized study of vinorelbine versus observation in patient responding to induction therapy. Proc Am Soc Clin Oncol,2001,20:309a.
4Maurizio Tonato.Final report of the adjuvant lung project italy (ALPI):an Italian? EORTC-LCG randomized trail of adjuvant chemotherapy in completely resected non-small cell lung cancer (NSCLC)[C].Proc ASCO,2002,Abstract:1157.
5Chevalier TL,Pignon JP,Bergman B,et al.Results of the randomized international adjuvant lung cancer trail (1ALT):ciplatinbased chemotherapy(CT) vs no CT in 1867 patients with resected non-small cell lung cancer (NSCLC)[J].Lung Cancer,2003,41 (52):3 -7.
6C.Soria and T.Le Chevalier.Is cisplatin still the best platinum compound in non-small-cell lung cancer[J].Annals of Oncology,2002,13:1515-1517.
7Kelly K,Crowley J,Bunn PA,et al.Randomized phase Ⅲ trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the retreatment of patients with advanced non-small cell lung cancer:a southwest oncology group trial[J].J Clin Oncol,2001,19(13):3210 -3218.
8Keller SM,Adak S,Wagner H,et al.A randomized trial of postoperative adjuvant therapy in patients with completely resected stage Ⅱ or ⅢA non-small-cell lung cancer.Eastern Cooperatie Oncology Group[J].N Mngl J Med,2000,343(17):1217～1222
9Scagliotti GV,Fossati R,Torri V,et al.Randomized study of adjuvant chemotherapy for completly resected stage Ⅰ,Ⅱ,or Ⅲ A non-smallcell Lung cancer[J].J Natl Cancer Inst,2003,95 (19):1453 ～ 1461
10Chevalier TL,Pignon JP,Bergman B,et al.Results of the Randomized International Adjuvant Lung Lancer Trail (IALT):ciplatin-based chemotherapy(CT) vs no CT in 1867 patients with resected non-small cell lung cancer (NSCLC)[J].Lung Cancer,2003,41(52):3～7
